The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...

Novo Nordisk A/S (NYSE:NVO), the Danish pharmaceutical giant renowned for its weight-loss drug Wegovy and diabetes treatment ...

The diabetes drugs Ozempic and Wegovy have been linked to an increased risk of sudden vision loss and blindness due to a rare ...

Is Novo Nordisk stock a buy? An analysis of $NVO, its weight loss drugs Ozempic and Wegovy, and market share competition with ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...

Today’s Forbes Daily covers Pacific tsunami activity after powerful quake, Trump breaks with Netanyahu over Gaza, the Forbes ...

As of 2024, Brazil's Semaglutide market was estimated at $581 million. The global market size for the GLP-1 (glucagon-like ...

More than 60 billion euros (£52 billion) has been wiped off the stock market value of Ozempic and Wegovy weight loss drug ...

A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic, were linked to a 33% lower risk of ...

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.

A new study reveals key predictors of successful weight loss on GLP-1RA drugs like Ozempic and Wegovy, including longer treatment duration, no diabetes, higher body fat, and muscle mass.

During the hearing, an official from Novo Nordisk will be questioned about the pricing they charge for Ozempic and ...